Title: Four
public biotechs are jumping in super antibiotic for superbugs Publication: Hankuk Economy (Hankyung) / Min-Soo Han Date: 2 Sep 2014 URL: link to website (contents in Korean)
Summary
·
Antibiotics has been one of
LegoChem’s core therapeutic areas since inception. LegoChem has been developing
three super antibiotics up until today. ·
The most advanced antibiotics is
Oxazolidinone antiobiotics (LCB01-0371) for the treatment of respiratory tract
and skin infection caused by gram-positive, drug-resistant super bacteria
including MRSA and VRE. ·
LCB01-0371 shows excellent safety
profile against mylosuppression, prompting longer treatment duration. ·
Next-generation Oxazolidinone
antibiotics (LCB01-0699) is the first-in-class with broad spectrum against
linezolid-resistant bacteria and some gram-negative bacteria. It is under
preclinical in collaboration with Medicilon/Longthera in China. ·
Cephalosporin antibiotics
(LCB10-0200), which is in preclinical in the UK, is against various
gram-negative bacillus including P. aeruginosa,
K. pneumonia, and A. baumanni. ·
According to an analyst from KDB
Daewoo Securities, preclinical results will likely be reflected in clinical
trials because antibiotics only kill bacterial cells unlike other drugs that
can influence the human metabolic system.
About LegoChem Biosciences LegoChem Biosciences, Inc. (LCB) is a
research-based biotechnology company dedicated to discovering, developing, and
commercializing innovative medicines by leveraging our chemistry expertise to
make conventional biologics targeted and more potent for the benefit of
patients with diseases of high unmet medical needs. We are advancing
sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants,
oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).
| 
